Prescribing overview
Incurin targets estrogen-responsive incontinence in spayed female dogs; its dose is not weight-based.
Key prescribing checks
- Evaluate other causes of urinary leakage before treatment, including conditions that need diagnostic testing. Lack of response should prompt reconsideration of the diagnosis.
- Do not combine with other estrogens. Review liver disease, glucocorticoids and reproductive status because the label describes gaps in safety evaluation.
- Safe use has not been evaluated in intact females, pregnant or lactating dogs, male dogs or dogs under one year.
- Monitor gastrointestinal and estrogenic changes. Hand washing and exposure precautions are relevant for staff administering the tablets.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Ovariohysterectomized female dogs
FDA-approved veterinary labelEstrogen-responsive urinary incontinence
Safety under one year unestablished.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Estrogen increases resting urethral muscle tone.
Absorption, distribution, metabolism and elimination
Oral absorption is rapid in dogs; enterohepatic recycling can produce multiple concentration peaks and complicate half-life estimation.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Incurin
U.S. estriol tablets for estrogen-responsive urinary incontinence in spayed female dogs.
Contraindications · when not to use
A formal contraindication list is not established in the reviewed source for this scope. This does not establish safety; confirm the exact product and full labeling.
Precautions & monitoring
- Liver-disease use and safety in intact females, pregnant/lactating dogs, male dogs or dogs under one year are unestablished. Assess other causes of incontinence; monitor estrogenic effects. Handler exposure precautions apply.
Reviewed U.S. label has no separate contraindications section; this is not a statement that no contraindications exist. The explicit estrogen combination prohibition is listed under interactions.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Reduced appetite, vomiting, vulvar changes and mammary enlargement may occur.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
| Species & indication | Labeled regimen | Eligibility & source |
|---|---|---|
| Spayed female dogs; safety <1 year unestablishedEstrogen-responsive urinary incontinenceIncurin 1 mg tablets | Initial 2 mg/dog Oral · Once daily Minimum 14 days initially; then lowest effective maintenance regimen | After control: step down to 1 mg/day then 0.5 mg/day, ≥7 days between adjustments; subsequently may use every other day. Maximum 2 mg/day; reassess diagnosis if ineffective. Verify full dosing label ↗ |
Do not combine with other estrogens.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Incurin
U.S. estriol tablets for estrogen-responsive urinary incontinence in spayed female dogs.
- Do not use with other estrogens. Concurrent glucocorticoids have not been evaluated.
Monitoring
Track continence and estrogenic/GI effects.
Client counseling
Wash hands after administration; childbearing/breastfeeding handlers need exposure caution.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Store ≤25°C; label permits excursions to 40°C.
Brands, formulations & ingredient identity
Active ingredients
estriol
Incurin identifies estriol. Estradiol and diethylstilbestrol are different estrogen drugs and should not appear as ingredient synonyms.
The U.S. product is an oral veterinary tablet. A shared hormone category does not establish interchangeability with a human or compounded estrogen formulation.
The label’s response-based adjustment approach differs from assuming that every drug is selected only by body weight. The prescriber must determine the individual plan.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Incurin
- Formulation
- Oral tablets
- Label / product scope
- Dogs
Indication specifically concerns spayed female dogs with estrogen-responsive incontinence.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →